Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Double-Blind Comparison of Fluvoxamine Versus Placebo in the Treatment of Compulsive Buying Disorder

A Double-Blind Comparison of Fluvoxamine Versus Placebo in the Treatment of Compulsive Buying... Nondepressed outpatients with a compulsive buying disorder were recruited by advertisement and word of mouth for inclusion in a controlled treatment trial. Following a 1-week single-blind placebo washout, subjects were randomly assigned to fluvoxamine (n = 12) or placebo (n = 11). Subjects received fluvoxamine (up to 300 mg daily) or placebo for 9 weeks. There were few dropouts. Outcome measures included the Yale–Brown Obsessive-Compulsive Scale—Shopping Version (YBOCS-SV), three Clinical Global Impressions (CGI) ratings, the Hamilton Rating Scale for Depression (HRSD), and the Maudsley Obsessive-compulsive Inventory (MOI). At the conclusion of the trial, 50% of fluvoxamine recipients and 63.6% of placebo recipients achieved CGI ratings of “much” or “very much” improvement, while 33% of fluvoxamine recipients were “very much” improved compared with 18% of placebo recipients (by endpoint analysis). Subjects in both treatment cells showed improvement as early as the second week of the trial, and for most, improvement continued during the 9-week study. There were no significant differences between fluvoxamine- and placebo-treated subjects on any of the outcome measures, with the exception that fluvoxamine recipients achieved greater improvement than placebo recipients on the MOI (p = .02). Adverse experiences were more frequent in the group receiving fluvoxamine, particularly nausea, insomnia, decreased motivation, and sedation. We conclude that in a short-term treatment trial of compulsive buying, subjects receiving fluvoxamine or placebo respond similarly. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

A Double-Blind Comparison of Fluvoxamine Versus Placebo in the Treatment of Compulsive Buying Disorder

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/a-double-blind-comparison-of-fluvoxamine-versus-placebo-in-the-GXRTakJbCh
Publisher
Springer Journals
Copyright
Copyright © 2000 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1009030425631
Publisher site
See Article on Publisher Site

Abstract

Nondepressed outpatients with a compulsive buying disorder were recruited by advertisement and word of mouth for inclusion in a controlled treatment trial. Following a 1-week single-blind placebo washout, subjects were randomly assigned to fluvoxamine (n = 12) or placebo (n = 11). Subjects received fluvoxamine (up to 300 mg daily) or placebo for 9 weeks. There were few dropouts. Outcome measures included the Yale–Brown Obsessive-Compulsive Scale—Shopping Version (YBOCS-SV), three Clinical Global Impressions (CGI) ratings, the Hamilton Rating Scale for Depression (HRSD), and the Maudsley Obsessive-compulsive Inventory (MOI). At the conclusion of the trial, 50% of fluvoxamine recipients and 63.6% of placebo recipients achieved CGI ratings of “much” or “very much” improvement, while 33% of fluvoxamine recipients were “very much” improved compared with 18% of placebo recipients (by endpoint analysis). Subjects in both treatment cells showed improvement as early as the second week of the trial, and for most, improvement continued during the 9-week study. There were no significant differences between fluvoxamine- and placebo-treated subjects on any of the outcome measures, with the exception that fluvoxamine recipients achieved greater improvement than placebo recipients on the MOI (p = .02). Adverse experiences were more frequent in the group receiving fluvoxamine, particularly nausea, insomnia, decreased motivation, and sedation. We conclude that in a short-term treatment trial of compulsive buying, subjects receiving fluvoxamine or placebo respond similarly.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 8, 2004

References

  • Fluvoxamine in the treatment of compulsive buying
    Black, DW; Monahan, P; Gabel, J
  • A report of 20 cases
    McElroy, SL; Keck, PE; Pope, HG
  • Treatment of compulsive shopping with antidepressants: A report of three cases
    McElroy, SL; Satlin, A; Pope, HG
  • Family history and psychiatric comorbidity in persons with compulsive buying: Preliminary findings
    Black, DW; Repertinger, S; Gaffney, GR; Gabel, J
  • Phenomenology and psychopathology of uncontrolled buying
    Lejoyeaux, M; Ades, J; Tassian, V; Solomon, J
  • Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic ef-ficacy and depressive illness
    Benfield, P; Ward, A
  • Efficacy of fluvoxamine in obsessive compulsive disorder
    Goodman, WK; Price, LH; Rasmussen, SA
  • A clinical screener for compulsive buying
    Faber, RJ; O'Guinn, TC
  • Developing a rating scale for primary depressive illness
    Hamilton, M
  • Reliability and validity of a scale to measure change in persons with compulsive buying
    Monahan, P; Black, DW; Gabel, J
  • The Behavior of Psychiatric Patients
    Murphy, DL; Pickar, DL; Alterman, IS
  • Structured Clinical Interview for DSM-III-R (SCID)
    Spitzer, RL; Williams, JBW; Gibbon, M
  • Structured Interview for DSM-III Personality Disorders, Revised (SIDP-R)
    Pfohl, B; Blum, N; Zimmerman, M
  • Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline
    Insel, TR; Murphy, DL; Cohen, RM
  • Obsessive-compulsive complaints
    Hodgson, RJ; Rachman, S
  • The Anxiety Disease
    Sheehan, DW
  • Compulsive buying: A review
    Black, DW
  • Born to Spend: How to Overcome Compulsive Spending
    Arenson, G
  • Women Who Shop Too Much: Overcoming the Urge to Splurge
    Wesson, C
  • Placebo response in panic disorder
    Coryell, WH; Noyes, R